Key facts
- It has raised $2.0M across 1 recorded rounds; the latest was Seed Round ($2.0M) in May 2022.
- Notable investors include Service Provider Capital, Calm Ventures, Biobrit, Electric Monkey Ventures, Portal Innovations — 6 tracked in total.
- RNAV8 Bio has filed 4 Form Ds with the SEC since 2023, most recently Mar 2025 ($2.0M sold to 42 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for RNAV8 Bio
Funding rounds
1 roundsAbout RNAV8 Bio
Developer of a technology designed to reduce human suffering by expanding the scope of messenger RNA (Ribonucleic Acid) therapeutics. The company offers an AI (artificial intelligence)-enabled wet lab and dry lab feedback loop that optimizes non-coding regions of messenger RNA strands to improve expression tuning and overall performance, enabling biotechnology companies and pharmaceutical companies to develop treatments for rare and common diseases with improved therapeutic outcomes.
- Sector
- Healthcare
- HQ
- Laguna Niguel, CA, United States
- Founded
- 2022
- Employees
- 4
- Website
- rnav8bio.com/
- Ownership
- Privately Held (backing)
RNAV8 Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in RNAV8 Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on RNAV8 Bio in its N-PORT filings yet. We sweep new filings monthly.